Raaj Medisafe India Limited
Raaj Medisafe India Limited Fundamental Analysis
Raaj Medisafe India Limited (RAAJMEDI.BO) shows moderate financial fundamentals with a PE ratio of 14.62, profit margin of 10.51%, and ROE of 29.19%. The company generates $0.7B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 42.8/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze RAAJMEDI.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakRAAJMEDI.BO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentRAAJMEDI.BO trades at attractive valuation levels.
Growth Score
ModerateRAAJMEDI.BO shows steady but slowing expansion.
Financial Health Score
WeakRAAJMEDI.BO carries high financial risk with limited liquidity.
Profitability Score
WeakRAAJMEDI.BO struggles to sustain strong margins.
Key Financial Metrics
Is RAAJMEDI.BO Expensive or Cheap?
P/E Ratio
RAAJMEDI.BO trades at 14.62 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, RAAJMEDI.BO's PEG of 0.87 indicates potential undervaluation.
Price to Book
The market values Raaj Medisafe India Limited at 3.86 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 5.60 times EBITDA. This is generally considered low.
How Well Does RAAJMEDI.BO Make Money?
Net Profit Margin
For every $100 in sales, Raaj Medisafe India Limited keeps $10.51 as profit after all expenses.
Operating Margin
Core operations generate 12.20 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $29.19 in profit for every $100 of shareholder equity.
ROA
Raaj Medisafe India Limited generates $8.63 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Raaj Medisafe India Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Raaj Medisafe India Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
RAAJMEDI.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
14.62
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.87
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.86
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.55
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.79
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.86
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.29
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How RAAJMEDI.BO Stacks Against Its Sector Peers
| Metric | RAAJMEDI.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 14.62 | 29.78 | Better (Cheaper) |
| ROE | 29.19% | 792.00% | Weak |
| Net Margin | 10.51% | -24634.00% (disorted) | Strong |
| Debt/Equity | 1.79 | 0.25 | Weak (High Leverage) |
| Current Ratio | 0.86 | 4.60 | Weak Liquidity |
| ROA | 8.63% | -18106.00% (disorted) | Weak |
RAAJMEDI.BO outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Raaj Medisafe India Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation